Daiichi Sankyo Loses One, Gains One In Oncology
This article was originally published in PharmAsia News
Daiichi Sankyo has unveiled disappointing results for one pipeline molecule that has now been suspended for lung cancer, but has gained another for breast cancer as it continues to develop its oncology portfolio.
You may also be interested in...
Phase III results for Daiichi Sankyo's FLT3 targeting quizartinib are in, but it's unclear as yet how the data will affect a niche, targeted hematology/oncology market.
Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.
Daiichi Sankyo is to continue with a multinational Phase III trial for its novel candidate for tenosynovial giant cell tumor despite cases of liver toxicity, but has stopped enrolment short of target and modified the protocol.